Agilent Technologies, Inc. $A Stock: Stone Summit Wealth LLC Lowers Holdings

Stone Summit Wealth LLC lessened its holdings in Agilent Technologies, Inc. (NYSE:A) by 16.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 15,167 shares of the medical research company’s stock after selling 3,025 shares during the quarter. Stone Summit Wealth LLC’s holdings in Agilent Technologies were worth $2,613,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. SHP Wealth Management purchased a new stake in Agilent Technologies during the 4th quarter worth about $26,000. Cedar Mountain Advisors LLC acquired a new position in shares of Agilent Technologies during the 1st quarter worth about $27,000. Markowski Investments purchased a new position in shares of Agilent Technologies in the 2nd quarter valued at about $27,000. MV Capital Management Inc. purchased a new position in Agilent Technologies in the fourth quarter valued at approximately $28,000. Finally, Keating Financial Advisory Services Inc. purchased a new position in shares of Agilent Technologies in the 2nd quarter valued at $31,000.

Insider Buying and Selling

In other Agilent Technologies news, Director Mikael Dolsten sold 634 shares of the company’s stock in a transaction on Friday, September 4th. The stock was sold at an average price of $151.38, for a total value of $95,974.92. Following the sale, the director owned 4,924 shares of the company’s stock, valued at approximately $745,395.12. This represents a 11.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Agilent Technologies Price Performance

Agilent Technologies stock opened at $171.66 on Wednesday. The company has a market cap of $48.40 billion, a P/E ratio of 28.27, a price-to-earnings-growth ratio of 2.61 and a beta of 1.21. Agilent Technologies, Inc. has a one year low of $108.35 and a one year high of $177.05. The business has a fifty day moving average of $157.13 and a two-hundred day moving average of $136.41. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.56 and a current ratio of 2.05.

Agilent Technologies (NYSE:A) last issued its earnings results on Wednesday, August 26th. The medical research company reported $1.62 earnings per share for the quarter, topping the consensus estimate of $1.49 by $0.13. The company had revenue of $1.88 billion for the quarter, compared to analyst estimates of $1.84 billion. Agilent Technologies had a net margin of 19.53% and a return on equity of 24.45%. The firm’s revenue for the quarter was up 8.1% compared to the same quarter last year. During the same period in the prior year, the business posted $1.37 earnings per share. Agilent Technologies has set its Q4 2026 guidance at 1.710-1.740 EPS and its FY 2026 guidance at 6.180-6.210 EPS. As a group, analysts predict that Agilent Technologies, Inc. will post 6.20 earnings per share for the current fiscal year.

Agilent Technologies Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 28th. Shareholders of record on Tuesday, October 6th will be given a dividend of $0.2550 per share. This represents a $1.02 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Tuesday, October 6th. Agilent Technologies’s payout ratio is presently 20.08%.

Key Headlines Impacting Agilent Technologies

Here are the key news stories impacting Agilent Technologies this week:

• Positive Sentiment: Analysts raised their targets: Morgan Stanley increased its target from $175 to $190 and maintained an “overweight” rating, while TD Cowen lifted its target from $180 to $196 and assigned a “buy” rating. The revisions suggest analysts see additional upside based on Agilent’s growth outlook. TD Cowen Adjusts Price Target on Agilent Technologies
• Positive Sentiment: Agilent agreed to acquire Proscia, a pathology software company, for $240 million upfront plus milestone payments, bringing the potential transaction value to approximately $270 million. Proscia’s AI-enabled digital pathology technology could strengthen Agilent’s scientific intelligence and diagnostic capabilities, while expanding its exposure to the growing pathology software market. Agilent to Acquire Proscia
• Positive Sentiment: Market growth provides a favorable backdrop: A new industry report projects the global metabolomics market will expand at a 17.3% compound annual growth rate through 2030. Agilent is identified as one of the key companies positioned to benefit from increased adoption of AI-assisted diagnostics and life-science research tools. Global Metabolomics Market Report 2026
• Neutral Sentiment: Agilent plans to expand its capabilities in China, potentially supporting long-term regional growth. However, the article does not provide specific investment amounts, timelines, or expected financial contributions, leaving the near-term earnings impact uncertain. Agilent to Expand Capabilities in China
• Negative Sentiment: The Proscia transaction introduces acquisition costs and execution risks, and milestone payments could increase the ultimate purchase price. Investors will likely watch for regulatory approvals, integration progress, and evidence that the deal contributes meaningfully to revenue and earnings.

Analysts Set New Price Targets

A has been the topic of several research analyst reports. Morgan Stanley lifted their price target on Agilent Technologies from $175.00 to $190.00 and gave the stock an “overweight” rating in a research report on Tuesday. Bank of America increased their price objective on Agilent Technologies from $155.00 to $180.00 and gave the stock a “buy” rating in a research report on Thursday, August 27th. Barclays lifted their target price on Agilent Technologies from $175.00 to $195.00 and gave the company an “overweight” rating in a research note on Wednesday, October 7th. Jefferies Financial Group began coverage on Agilent Technologies in a research note on Thursday, July 9th. They issued a “hold” rating and a $135.00 target price on the stock. Finally, Citigroup upped their price target on Agilent Technologies from $185.00 to $190.00 and gave the stock a “buy” rating in a research note on Thursday, August 27th. Fifteen equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, Agilent Technologies has a consensus rating of “Moderate Buy” and an average price target of $173.65.

Agilent Technologies Profile

Agilent Technologies, Inc is an analytical measurement and laboratory technology company serving the life sciences, diagnostics, pharmaceutical, chemical, environmental, food, energy and academic research markets. Its solutions help laboratories analyze the composition, quality and performance of materials, biological samples and other substances.

The company’s products and services include liquid and gas chromatography systems, mass spectrometry instruments, spectroscopy equipment, laboratory automation tools, software, consumables and supplies.